Asahi Kasei gets FDA approval for herpes drug Hovilpri for immunocompromised patients, validating its $920M acquisition of ...
Brent Saunders exits as Bausch + Lomb CEO by mutual agreement, replaced interim by Thomas Appio. Shares down 3%. Company to ...
Mirum's Livmarli, First Tracks' ANB033, and Tortugas' obuprazine showed positive Phase 3, 1b, and 2b trial results in liver ...
A trial testing admilparant in IPF succeeded at the lower 60 mg dose, while the higher 120 mg dose failed. And the GEP-NET ...
AstraZeneca says an imbalanced adult subgroup sank its Ph3 HICKORY trial of efzimfotase alfa in hypophosphatasia as the FDA ...
Welcome back to Endpoints Weekly! We unveiled our 2026 Women in Biopharma special project on Monday. Our team pored through nearly 200 nominations to reach this year’s list of 20 ...
Curium prices Bexlutry, its copycat of Novartis’ radioligand Lutathera, at $63,524 per infusion, about 5% below the original.
Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient ...
City Therapeutics eyes $158M IPO; Iambic Therapeutics targets $135M; Alchemist Capital launches with $100M; Life Biosciences ...
IPOs on Nasdaq, backed by Eli Lilly, focusing on Treg science for autoimmune disorders. Pipeline includes TRB-061 and a CD30 agonist for IBD.
PhRMA says FDA will get money it can spend only on hiring and keeping staff, to restore reviewer levels after the HHS layoffs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results